Merrimack Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Merrimack Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
Merrimack Pharmaceuticals: 22 sponsored US clinical trials, none currently recruiting.
Merrimack Pharmaceuticals sponsors 22 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 19 completed. 1 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Her2 Amplified Solid Tumors, with 1 trials.
Top-decile sponsor footprint
Merrimack Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
22 total, page 1 of 1
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
NCT02538627
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
NCT02399137
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
NCT02213744
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
NCT01774851
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
NCT01733004
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
NCT01520389
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
NCT01494506
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
NCT01451632
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
NCT01447225
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
NCT01447706
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
NCT01421472
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
NCT01304784
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
NCT01209195
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
NCT01151046
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
NCT01097460
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
NCT00994123
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
NCT00911898
Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
NCT00734305
A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis
NCT00458146
Phase 2 Study of MM-093 to Treat Patients With Uveitis
NCT00444743
Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis
NCT00147329
Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)
NCT00105976
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 10 |
| Phase 3 | 1 |
How the Merrimack Pharmaceuticals early-phase archive is shaped
22 indexed studies, none listed as recruiting (0% open); 19 completed (86%).
Phase mix: 1 late (III/IV) vs 21 early (I/II) (early-phase heavy).
Top condition: Her2 Amplified Solid Tumors (1 trial), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Merrimack Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 22 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Merrimack Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 archived trials
- Alaunos Therapeutics · 22 trials · 0% recruiting
- Alexza Pharmaceuticals · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Fate Therapeutics · 22 trials · 14% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Merrimack Pharmaceuticals page
22 registered trials is a research-attention snapshot, not an endorsement of Merrimack Pharmaceuticals or any single study.
- None of Merrimack Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Her2 Amplified Solid Tumors is the condition Merrimack Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Her2 Amplified Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Merrimack Pharmaceuticals pipeline card: 22 registered trials from official public datasets.Report a data error.